These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34289749)

  • 61. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.
    Cargnin S; Shin JI; Genazzani AA; Nottegar A; Terrazzino S
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):577-588. PubMed ID: 33005979
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Infusion Reactions in HER2-Positive Gastric Cancer: Switching from Trastuzumab to Its Biosimilar.
    Abe T; Sagara A; Suzuki T; Okada D; Matsuzaka K; Nakayama T
    Biol Pharm Bull; 2024; 47(8):1452-1455. PubMed ID: 39168631
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interstitial pneumonitis associated with trastuzumab emtansine.
    Alkan A
    J Oncol Pharm Pract; 2019 Oct; 25(7):1798-1800. PubMed ID: 30426834
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
    Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
    Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
    Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
    Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.
    Miranda-Hernández MP; López-Morales CA; Piña-Lara N; Perdomo-Abúndez FC; Pérez NO; Revilla-Beltri J; Molina-Pérez A; Estrada-Marín L; Flores-Ortiz LF; Ruiz-Argüelles A; Medina-Rivero E
    Biomed Res Int; 2015; 2015():874916. PubMed ID: 26682224
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
    Nunes T; Pons T; Hou X; Van Do K; Caron B; Rigal M; Di Benedetto M; Palpant B; Leboeuf C; Janin A; Bousquet G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):306. PubMed ID: 31299997
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 74. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
    Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
    Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin
    Schmidt M; KÜmmel S; Ruf-Doerdelmann A; Distelrath A; Wacker J; Schmatloch S; Busch-Liles S; LÜdtke-Heckenkamp K
    Anticancer Res; 2021 Jan; 41(1):485-496. PubMed ID: 33419847
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).
    Hurst S; Ryan AM; Ng CK; McNally JM; Lorello LG; Finch GL; Leach MW; Ploch SA; Fohey JA; Smolarek TA
    BioDrugs; 2014 Oct; 28(5):451-9. PubMed ID: 25001079
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars.
    Azuz S; Newton M; Bartels D; Poulsen BK
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1495-1501. PubMed ID: 34008071
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.
    Pivot X; Deslypere JP; Park LS; Kim MJ; Lee W; Lee J
    Clin Ther; 2018 Mar; 40(3):396-405.e4. PubMed ID: 29502805
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology.
    Brain E; Caillet P; de Glas N; Biganzoli L; Cheng K; Lago LD; Wildiers H
    J Geriatr Oncol; 2019 Nov; 10(6):1003-1013. PubMed ID: 31235436
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
    Xu B; Zhang Q; Sun T; Li W; Teng Y; Hu X; Bondarenko I; Adamchuk H; Zhang L; Trukhin D; Wang S; Zheng H; Tong Z; Shparyk Y; Wang Q;
    BioDrugs; 2021 May; 35(3):337-350. PubMed ID: 33826080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.